24/7 Customer Support

+1 718 473 0872

Imexpharm - Company Report, 2011

  • January 2011
  • 11 pages

Download This Report Now!

We value your privacy and will never rent or sell your email address.
Privacy Policy by TRUSTe

  • Segment Coverage

    Drug And Medicatio...  

  • Geographic Coverage

    Vietnam  

  • Type of data

    Company Financials  

    Forecast  

  • IMP 1
  • Imexpharm (IMP - HoSE: FY2011 results and FY2012 outlook - FY2011 a little under
  • target while forward growth prospects looks rather anemic for now. 1
  • Investment Conclusion 2
  • Sales by segment 3
  • COMPANY PROFILE 7
  • Scope of business 7
  • Sales breakdown in FY2011 7
  • Products, Services and Market 7
  • Ownership structure as of Feb. 2012 7
  • Position in the industry 7
  • Business strategy 8
  • Qualifications 8
  • Earnings model 1
  • Snapshot 2
  • COGS by segment 3
  • Gross profit by segment 3
  • Net financial income 4
  • FY2012 Outlook 5
  • Company History 7
  • Trading segment 3% 7
  • SWOT 8
  • FINANCIAL RATIO 9
  • ROA - ROE movement (%) 10
  • Sales - Net profit movement (VNDmil) 10
  • Unit: VNDmillion 10

Refine your search results

Purchase Reports From Reputable Market Research Publishers

World Drug and Medication: Typhoid Fever – Pipeline Review, H2 2011

World Drug and Medication: Typhoid Fever – Pipeline Review, H2 2011

  • $ 2 000
  • Company report
  • August 2014
  • by Global Markets Direct

Ependymoma – Pipeline Review, H2 2011 Global Industries Direct’s, 'Ependymoma - Pipeline Review, H2 2011', provides an overview of the Ependymoma therapeutic pipeline. This report provides data on ...

World Drug and Medication: Uveitis - Pipeline Review, H2 2011

World Drug and Medication: Uveitis - Pipeline Review, H2 2011

  • $ 2 000
  • Company report
  • August 2014
  • by Global Markets Direct

This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

Drug and Medication in United States: POZEN Inc. – Product Pipeline Review – H2 2011

Drug and Medication in United States: POZEN Inc. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the POZEN Inc.’s research and development focus. The report includes data on current developmental pipeline, complete with latest ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.